Maintenance therapy in IBD

Inflammatory Bowel Diseases

Volumn 4, Issue 4, 1998, Pages 292-301

  Tremaine, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DIET THERAPY; DRUG ADMINISTRATION; FEMALE; HUMAN; LONG TERM CARE; MALE; PREGNANCY; PREGNANCY COMPLICATION; PROGNOSIS; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PROGNOSIS;

EID: 0008700094     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-199811000-00007     Document Type: Conference Paper

References (34)

1. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo controlled, dose-ranging study. Gastroenterology 1996;110:45-51.
2. Sandborn WJ. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology 1995;109:1001-3.
3. Thomas GA, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995; 332:988-92.
4. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-9.
5. Ewe K, Herfarth C, Makhow H, Jesdinsky HJ. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 1989; 42:224-32.
6. Steinhart HA, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89;216-24.
7. Hanauer SB, and the Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996;124:204-11.
8. Miner PB Jr, Hanauer SB, Robinson MR, et al. Safety and efficacy of controlled release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995;40:296-304.
9. Travis SP, Tysk C, de Silva HJ, Sandberg-Gertzen H, Jewell DP, Jamerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994;35:1282-6.
10. Green JR, Swan CH, Rowlinson A, Gibson JA, Brown P, Kerr GD, Swarbrick ET, Thornton P. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992;6:647-52.
11. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M, and the Italian IBD Study Group. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992;103:363-8.
12. Bresci G, Petrucci A, Banti S. 5-Aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study, Int J Clin Pharmacol Res 1991;11:200-2.
13. Caprilli R, Anreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid: Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994;8:35-43.
14. Brignola C, Cottone M, Pera A, et al. Mesalamine in the Prevention of Endoscopic Recurrence after intestinal resection for Crohn's Disease. Gastroenterology 1995;108:345-9.
15. Gendre JP, Mary JY, Glorent C, et al. Oral mesalamine (Pentasa as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Group d'Etudes Tharapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993;104:435-9.
16. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn s disease: a meta-analysis. Am J Gastroenterol 1994;89:692-8.
17. Biddle WL, Greenberger NJ, Swan JT, et al. 5-aminosalicylic enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988;94:1075-9.
18. d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997;92:1143-7.
19. D'Arienzo A, Panarese A, D'Armiento FP, Lancia C, Quattrone P, Giannattasio F, Boscaino A, Mazzacca G. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990;85:1079-82.
20. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305(6844):20-2.
21. Fernandez-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, Planas R, Gassull MA. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498-9.
22. O'Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2(8097):955-7.
23. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99:1347-51.
24. Korelitz B, Hanauer, Rutgeerts P, et al. Post-operative prophylazis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multi-center trial [Abstr.]. Gastroenterology 1998;114:A1011.
25. Kozarek RA, Patterson DJ, Gelfand, et al. Long-term use or Methotrexate in inflammatory bowel disease: severe disease 3, drug therapy 2. Seventh Inning Stretch. Gastroenterology 1992; 702:A648.
26. Feagan BG, Rochon J, Fedorak RN, et al, for The North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
27. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-7.
28. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
29. Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomized controlled trial. Gut 1992;33:922-8.
30. Greenfield SM, Green AT, Teare JP, et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 1993;7:159-66.
31. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's Disease. N Eng J Med 1996;334:1557-60.
32. Jones VA, Dickinson RJ, Workman E, et al. Crohn's disease: maintenance of remission by diet. Lancet 1985;2(8448):177-80.
33. Pearson M, Teahon K, Levi AJ, et al. Food intolerance and Crohn's disease. Gut 1993;34:783-7.
34. Rutgeerts P, D'Haens G, van Deventer SJH, et al. Retreatment with anti-TNF-α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease [Abstract]. Gastroenterology 1997;112:A1078.